

Global Non-Alcoholic Steatohepatitis
Market: Analysis By Drug Type (Vitamin E
& Pioglitazone, Ocaliva, Elafibranor,
Selonsertib & Cenicriviroc and Others), By
Application Type (Treatment and
Diagnosis), By Distribution Type (Retail
Pharmacies, Hospital Pharmacies and
Online Pharmacies), By Region Size and
Trends with Impact of COVID-19 and
Forecast up to 2027

January 2023



Global Non-Alcoholic Steatohepatitis Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Impact Of COVID 19

Dynamics

Competitive Landscape

Company Profiling

Global Non-Alcoholic Steatohepatitis Market: Coverage

Scope of the Report

Attributes	Details
Title	Global Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc and Others), By Application Type (Treatment and Diagnosis), By Distribution Type (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027
Coverage	Global and Regional
Regional Coverage	North America (The US, Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea and Rest of Asia Pacific), Latin America and Middle East and Africa.
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2022-2027
Competition in the Market	Consolidated
Key Players	Intercept Pharmaceuticals, Inc., Novartis AG, Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., and BioPredictive

Global Non-Alcoholic Steatohepatitis Market: Coverage

Executive Summary

Non-Alcoholic Steatohepatitis (NASH) is an inflammatory liver disease associated with excessive fat accumulation in the liver (steatosis), hepatocellular ballooning, and inflammation. NASH is the second stage of non-alcoholic fatty liver disease (NAFLD) that has progressed to the point of liver inflammation and cell damage. The global non-alcoholic steatohepatitis (NASH) market in 2021 stood at US\$1.65 billion, and is likely to reach US\$15.04 billion by 2027. The market would grow at a CAGR of 50.47% over the projected period of 2022-2027.


The global non-alcoholic (NASH) steatohepatitis market can be segmented on the basis of drug type (vitamin e & pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc and others), application type (treatment and diagnosis) and distribution type (retail pharmacies, hospital pharmacies and online pharmacies). The non-alcoholic steatohepatitis (NASH) treatment market is both the largest and fastest growing segment of global non-alcoholic steatohepatitis (NASH) market owing to increased prevalence of NASH, expected launch of new pipeline drugs by pharmaceutical companies and development of various potential pathways for NASH treatments.

The COVID-19 brought in many changes in the world in terms of reduced productivity, loss of life, business closures, lockdown and closing down of factories and organizations. Lockdown policies imposed by the government led to an increase in adoption of sedentary lifestyle, rise in consumption of processed food containing polyunsaturated fatty acids, decreased regular exercises and increased consumption of fructose-rich diets, risk factors associated with increased likelihood of developing NASH. COVID-19 pandemic also contributed towards a rise in cardiovascular & metabolic risk factors along with appearance of new chronic pathologies, having a positive effect on the market in terms of increased demand for current treatment practices, diagnostic tools and emerging drugs for the treatment of NASH. Therefore, the global impact of COVID-19 on non-alcoholic steatohepatitis market turned out to be positive.

The global non-alcoholic (NASH) steatohepatitis has increased from 2020-2021 and projections are made that the market would continue to rise in the next five years i.e. 2022-2027. The market has seen a positive growth in the recent years owing to rising prevalence of non-alcoholic steatohepatitis, increasing adoption of sedentary lifestyle, rising cases of associated chronic diseases, rising health awareness, etc. Further, the market is expected to grow as a result of increasing integration of artificial intelligence (AI), digitalization, increased promotion of pipeline drugs, etc. Yet the market faces some challenges such as absence of low cost and definitive diagnostic methods, regulatory compliance, etc.

Non-Alcoholic Steatohepatitis Market: Global Analysis


Global Non-Alcoholic Steatohepatitis Market by Value



Global Non-Alcoholic Steatohepatitis market was valued at US\$... billion in 2021 and is anticipated to reach up to US\$... billion by 2027 from US\$... billion in 2022, with a CAGR of xx%.

Non-Alcoholic Steatohepatitis Market: Global Analysis


Global Non-Alcoholic Steatohepatitis Market by Drug Type; 2021 and 2027



Drug Type	Share
Vitamin E & Pioglitazone	xx%
Ocaliva	xx%
Elafibranor	xx%
Selonsertib & Cenicriviroc	xx%
Others	xx%

Non-Alcoholic Steatohepatitis Market: Global Analysis

Global Non-Alcoholic Steatohepatitis Market by Application Type; 2021



Application Type	Share
Treatment	xx%
Diagnosis	xx%


Global Non-Alcoholic Steatohepatitis Market by Distribution Type; 2021



Distribution Type	Share
Retail Pharmacies	xx%
Hospital Pharmacies	xx%
Online Pharmacies	xx%


Non-Alcoholic Steatohepatitis Market: Global Analysis

Global Non-Alcoholic Steatohepatitis Market by Region; 2021




Non-Alcoholic Steatohepatitis Market: Drug Type Analysis

Global Vitamin E & Pioglitazone Non-Alcoholic Steatohepatitis Market by Value




Global Others Non-Alcoholic Steatohepatitis Market by Value




Drug Type	CAGR (2022-2027)
Vitamin E & Pioglitazone	xx%
Ocaliva	xx%
Elafibranor	xx%
Selonsertib & Cenicriviroc	xx%
Others	xx%

Non-Alcoholic Steatohepatitis Market: Application Type Analysis

Global Non-Alcoholic Steatohepatitis Treatment Market by Value




Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value




Application Type	CAGR (2022-2027)
Treatment	xx%
Diagnosis	xx%

Non-Alcoholic Steatohepatitis Market: Distribution Type Analysis

Global Retail Non-Alcoholic Steatohepatitis Market by Value




Global Online Non-Alcoholic Steatohepatitis Market by Value




Distribution Type	CAGR (2022-2027)
Retail Pharmacies	xx%
Hospital Pharmacies	xx%
Online Pharmacies	xx%

Non-Alcoholic Steatohepatitis Market: Regional Analysis

North America Non-Alcoholic Steatohepatitis Market by Value




Asia Pacific Non-Alcoholic Steatohepatitis Market by Value



Region	CAGR (2022-2027)
North America	xx%
Europe	xx%
Asia Pacific	xx%
Middle East and Africa	xx%
Latin America	xx%

North America Non-Alcoholic Steatohepatitis Market: An Analysis


North America Non-Alcoholic Steatohepatitis Market by Region; 2021



Region	Share (2021)	CAGR (2022-2027)
The US	xx%	xx%
Canada	xx%	xx%
Mexico	xx%	xx%

Asia Pacific Non-Alcoholic Steatohepatitis Market: An Analysis

Asia Pacific Non-Alcoholic Steatohepatitis Market by Region; 2021



Region	Share (2021)	CAGR (2022-2027)
China	xx%	xx%
Japan	xx%	xx%
South Korea	xx%	xx%
India	xx%	xx%
Australia	xx%	xx%
Rest of Asia Pacific	xx%	xx%


Europe Non-Alcoholic Steatohepatitis Market: An Analysis

Europe Non-Alcoholic Steatohepatitis Market by Region; 2021



Region	Share (2021)	CAGR (2022-2027)
Germany	xx%	xx%
UK	xx%	xx%
France	xx%	xx%
Italy	xx%	xx%
Spain	xx%	xx%
Rest of Europe	xx%	xx%

Global Non-Alcoholic Steatohepatitis Market: Dynamics



Global Non-Alcoholic Steatohepatitis Market: Competitive Landscape

Players Profiled

- ❑ Intercept Pharmaceuticals, Inc.
- ❑ Novartis AG
- ❑ Siemens Healthineers AG
- ❑ AstraZeneca PLC
- ❑ Galectin Therapeutics Inc.
- ❑ GENFIT S.A.
- ❑ Madrigal Pharmaceuticals, Inc.
- ❑ Inventiva S.A.
- ❑ ONE WAY LIVER, S.L.
- ❑ Galmed Pharmaceuticals Ltd.
- ❑ Cirius Therapeutics
- ❑ Prometheus Laboratories Inc.
- ❑ BioPredictive